Landscape of the field taar1-schizophrenia, mapped through the Amass MCP. Generated 2026-10-09 after run update-1. Every figure on this page is computed from the ledgers.
Nothing new in the field and no change on a tracked column.
Not due this run: BiomedCore, PatentCore.
Registry records in scope; a trial registered twice counts twice, a record naming two drugs counts under both.
Active: recruiting, not yet recruiting, enrolling by invitation, active not recruiting. Stopped: terminated, withdrawn, suspended. Other statuses are not plotted.
In-scope papers by publication year; the current year is partial.
One count per family, by the earliest priority date in scope.
| Papers per year | Count |
|---|---|
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 9 |
| 2020 | 5 |
| 2021 | 20 |
| 2022 | 17 |
| 2023 | 21 |
| 2024 | 23 |
| 2025 | 17 |
| 2026 | 15 |
| Patent families per priority year | Count |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 0 |
| 2016 | 2 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 2 |
| 2021 | 9 |
| 2022 | 8 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 0 |
| 2026 | 0 |
A record naming two drugs counts under both. A target entity counts gene records, papers and patents, not trials. A class entity takes the records that name no drug or target.
| Entity | Kind | Trials | Phase 3 | Phase 2 | Phase 1 | Active | Completed | Stopped | With results | Papers | Papers, last 24 months | Patent families | Authorizations | Drug records |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ulotaront | drug | 43 | 14 | 4 | 13 | 14 | 24 | 3 | 11 | 39 | 6 | 7 | 0 | 2 |
| ralmitaront | drug | 9 | 0 | 2 | 3 | 0 | 6 | 1 | 4 | 2 | 1 | 0 | 0 | 1 |
| selutaront | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| LK00764 | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| AP163 | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| PCC0105004 | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| TAAR1 | target | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 23 | 15 | 0 | 0 |
| TAAR1 agonists | class | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 3 | 0 | 0 |
| Unassigned | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 4 | 18 | 0 | 0 |
Field taar1-schizophrenia, mapped through the Amass MCP on 2026-10-08. Every number below comes from the run summary (log/summary-baseline-1.md), which the helper computed from the ledgers.
TAAR1 agonism in psychiatry is a two-drug clinical field: ulotaront (SEP-363856) carries the development programme, ralmitaront's programme has stopped, and four newer agonists named in the literature (selutaront, LK00764, AP163, PCC0105004) have no trial record yet. The map holds 52 in-scope trial records, 159 papers, 45 patent families, 3 drug records and the TAAR1 gene record; the target-level literature alone has 23 papers from the last 24 months. No TAAR1 agonist is approved anywhere, so there is no authorization to track yet.
| Entity | Kind | Trials | Phase 3 | Phase 2 | Phase 1 | Active | Completed | Stopped | With results | Papers | Papers, last 24 months | Patent families | Authorizations | Drug records |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ulotaront | drug | 43 | 14 | 4 | 13 | 14 | 24 | 3 | 11 | 39 | 6 | 7 | 0 | 2 |
| ralmitaront | drug | 9 | 0 | 2 | 3 | 0 | 6 | 1 | 4 | 2 | 1 | 0 | 0 | 1 |
| selutaront | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| LK00764 | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| AP163 | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| PCC0105004 | drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| TAAR1 | target | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 23 | 15 | 0 | 0 |
| TAAR1 agonists | class | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 3 | 3 | 0 | 0 |
| Unassigned | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 4 | 18 | 0 | 0 |
Ulotaront. 43 trial records, of which 14 are Phase 3, 4 Phase 2 and 13 Phase 1; 14 are active and 24 completed, 3 stopped, and 11 have posted results. The trial records include registrations of the same study in several registries (an NCT record and a Japanese jRCT record for one trial, for instance), which is why the count is of records rather than studies. 39 papers name the drug, 6 of them from the last two years, and 7 patent families cover it. DrugCore holds two records, the base compound and its hydrochloride.
Ralmitaront. 9 trial records, 2 Phase 2 and 3 Phase 1, none active: 6 completed, 1 stopped, 4 with results. Two papers and one drug record; no patent family names it.
Newer agonists. Selutaront, LK00764, AP163 and PCC0105004 each appear in one paper and in no trial. They have no DrugCore record yet, which is how ChEMBL-anchored data treats compounds this new; their names are in the plan, so a registered trial will be picked up by the next update.
Target-level work. 111 papers and 15 patent families are about TAAR1 as a target without naming one of these drugs, 23 of the papers from the last two years. 20 papers and 18 patent families match neither a drug nor the target by name (class reviews, generic patent titles) and are listed under Unassigned on the Landscape sheet.
None. No TAAR1 agonist holds an FDA or EMA authorization; the 20 RegulatoryCore records the searches returned are other products whose label text mentions an agonist, and all are screened out with that reason.
All three anchor trials were found by search, including the Japanese trial under both its NCT and jRCT registrations. Of the 32 trials linked from the ulotaront and ralmitaront drug records, the searches had reached every one. On TrialCore the code, mechanism and sponsor facets saturated; the drug facet, and the paper and patent facets, were still producing when the run ended, so a later "extend" would add papers and patents before it adds trials. 23 records are unsure and need a call: 4 trials whose records do not state the mechanism (two SEP-380135 trials, one SEP-479, one VV119), 6 papers at the boundary of the scope (broad reviews and trace-amine physiology), and 13 patents, among them a likely ulotaront use patent whose abstract never names TAAR1.
The workbook taar1-schizophrenia.xlsx opens on the Landscape sheet: the table above, the scope, the coverage box and these instructions. Key records lists the Phase 2 and later trials and the authorizations, one line each. The Core sheets (TrialCore, BiomedCore, DrugCore, GeneCore, RegulatoryCore, PatentCore) hold every in-scope and unsure record with its decision and reason; filter on the decision column to see the unsure ones. Excluded holds everything that was screened out, with the reason. The folder landscapes/taar1-schizophrenia is the memory for updates, so keep it; say "run the update" to get what changed since this map, by drug and by Core. The in-scope trials can also be exported as a watchlist for amass-watchlist-monitor, which tracks those records exactly.
| Drug | Trial | Phase | Status | Sponsor | Start | Enrolment | Results |
|---|---|---|---|---|---|---|---|
| ulotaront | NCT06894212 A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia | PHASE3 | ACTIVE_NOT_RECRUITING | Otsuka Pharmaceutical Development & Comm | 2025-02-28 | 538 | |
| ulotaront | NCT07225712 A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia | PHASE3 | RECRUITING | Otsuka Pharmaceutical Co., Ltd. | 2025-12-22 | 100 | |
| ulotaront | NCT07759128 A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder | PHASE3 | RECRUITING | Otsuka Pharmaceutical Development & Comm | 2026-07-28 | 576 | |
| ulotaront | NCT07767903 A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder | PHASE3 | RECRUITING | Otsuka Pharmaceutical Development & Comm | 2026-08-06 | 384 | |
| ulotaront | NCT07786454 A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder | PHASE3 | NOT_YET_RECRUITING | Otsuka Pharmaceutical Development & Comm | 2026-10-06 | 1120 | |
| ulotaront | NCT04072354 A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With | PHASE3 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2019-09-17 | 463 | yes |
| ulotaront | NCT04092686 A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic Peopl | PHASE3 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2019-10-14 | 464 | yes |
| ulotaront | NCT04109950 A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With S | PHASE3 | TERMINATED | Otsuka Pharmaceutical Development & Comm | 2019-11-20 | 463 | |
| ulotaront | NCT04115319 A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. | PHASE3 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2019-11-21 | 305 | yes |
| ulotaront | NCT05359081 A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophreni | PHASE3 | TERMINATED | Sumitomo Pharma Co., Ltd. | 2022-05-16 | 68 | |
| ulotaront | NCT05628103 A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia | PHASE3 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2022-12-19 | 101 | yes |
| ulotaront | NCT05741528 An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-3638 | PHASE3 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2023-03-31 | 75 | yes |
| ulotaront | NCT04825860 A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophre | PHASE2/PHASE3 | TERMINATED | Sumitomo Pharma Co., Ltd. | 2021-03-29 | 83 | |
| ulotaront | NCT05729373 A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anx | PHASE2/PHASE3 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2023-03-08 | 434 | |
| ulotaront | NCT02969382 A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia | PHASE2 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2016-12-05 | 245 | yes |
| ulotaront | NCT02969369 A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease P | PHASE2 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2016-12-31 | 39 | yes |
| ulotaront | NCT02970929 An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia | PHASE2 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2017-01-31 | 157 | yes |
| ralmitaront | NCT03669640 A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective | PHASE2 | TERMINATED | Hoffmann-La Roche | 2018-12-04 | 131 | yes |
| ralmitaront | NCT04512066 A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerb | PHASE2 | COMPLETED | Hoffmann-La Roche | 2020-09-08 | 287 | yes |
| ulotaront | NCT05593029 A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder | PHASE2 | COMPLETED | Otsuka Pharmaceutical Development & Comm | 2022-11-09 | 929 |
No authorization in scope: no drug of this field holds an FDA or EMA authorization in Amass.
Saturated: DrugCore drug, TrialCore code, TrialCore mechanism, TrialCore sponsor, BiomedCore drug, RegulatoryCore drug. Still producing when the run ended: DrugCore mechanism, DrugCore target, GeneCore target, TrialCore drug, BiomedCore code, BiomedCore mechanism, RegulatoryCore mechanism, PatentCore mechanism, PatentCore drug, PatentCore sponsor.
Search is relevance-ranked and capped per call, so the map is as complete as the plan and its saturation say. Date-filtered searches cannot see deletions, results-only revisions, label or SmPC section-only revisions, or in-place publication-date corrections; PatentCore updates find newly published patents only.